Currently, major concerns about the safety and efficacy of RNA interference (RNAi)-based bone anabolic strategies still exist because of the lack of direct osteoblast-specific delivery systems for osteogenic siRNAs. Here we screened the aptamer CH6 by cell-SELEX, specifically targeting both rat and human osteoblasts, and then we developed CH6 aptamer-functionalized lipid nanoparticles (LNPs) encapsulating osteogenic pleckstrin homology domain-containing family O member 1 (Plekho1) siRNA (CH6-LNPs-siRNA). Our results showed that CH6 facilitated in vitro osteoblast-selective uptake of Plekho1 siRNA, mainly via macropinocytosis, and boosted in vivo osteoblastspecific Plekho1 gene silencing, which promoted bone formation, improved bone microarchitecture, increased bone mass and enhanced mechanical properties in both osteopenic and healthy rodents. These results indicate that osteoblast-specific aptamerfunctionalized LNPs could act as a new RNAi-based bone anabolic strategy, advancing the targeted delivery selectivity of osteogenic siRNAs from the tissue level to the cellular level.
Metabolic skeletal disorders associated with impaired bone formation (for example, osteoporosis) remain major clinical challenges. RNA interference (RNAi)-based approaches aimed at promoting osteoblastic bone formation may hold therapeutic potential 1,2 . However, a major bottleneck for translating RNAi-based approaches into clinical application is the lack of osteoblast-specific osteogenic siRNA delivery systems 3 .
Plekho1 (also known as casein kinase-2 interacting protein-1 (CKIP-1)) has been identified as an intracellular negative regulator of bone formation that does not affect bone resorption 4 . Previously we developed a targeting system involving dioleoyl trimethylammonium propane (DOTAP)-based cationic liposomes attached to six repetitive sequences of aspartate, serine and serine ((AspSerSer) 6 ), which had good affinity for the physiochemical features of the bone-formation surface when compared to the bone-resorption surface. By using this system, osteogenic Plekho1 siRNA was specifically delivered to the bone-formation surface to promote bone formation 5 . However, as the system was not specific to osteoblasts at the cellular level, other non-osteoblasts near the bone-formation surface, including endothelial cells and lymphocytes, may also be targeted, which arouses concerns about efficacy and potential toxic side effects [5] [6] [7] . In addition, other potential concerns, including mononuclear phagocyte system (MPS)-induced dose reduction 8, 9 , inefficient nanoparticle extravasation Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy caused by large particle size (larger than bony sinusoids (80-100 nm)) 5, 10 and detrimental hepatocyte accumulation of siRNA 11 , should also be considered by drug developers.
Here we sought to develop an osteoblast-specific delivery system for osteogenic siRNAs. First we used cell-based systematic evolution of ligands by exponential enrichment (cell-SELEX) to select osteoblastspecific aptamers, which are single-stranded oligonucleotides that use distinct tertiary structures to specifically bind to target cells 12, 13 . By performing positive selection with osteoblasts and negative selection with hepatocytes and peripheral blood mononuclear cells (PBMCs), we aimed to screen an aptamer that could achieve direct osteoblastspecific delivery of osteogenic siRNAs and minimal hepatocyte and PBMC accumulation of osteogenic siRNAs. Second, using lipid nanoparticles (LNPs), which are <90 nm (ref. 14) and have high polyethylene glycol (PEG) shielding, as the siRNA carriers, we aimed to realize efficient siRNA extravasation and reduce MPS uptake 15, 16 .
The osteoblast-specific aptamer CH6 was selected by cell-SELEX. When rendered with nuclease-resistance and conjugated to LNPs encapsulating osteogenic Plekho1 siRNA, CH6 achieved osteoblastspecific delivery of siRNAs and facilitated bone formation in osteopenic and healthy rodents. This demonstrates a real osteoblast-specific delivery system at the cellular level.
RESULTS

Selection of osteoblast-specific aptamers
We used rat primary osteoblasts to select aptamers by cell-SELEX from a library composed of 10 15 different ssDNA sequences. With increasing rounds of selection we observed progressive enhancement of fluorescence intensity for fluorescein amidite (FAM)-labeled ssDNA pools in target cells (rat primary osteoblasts) by flow cytometry analysis, whereas we observed no obvious change of fluorescence intensity in non-target cells (rat liver cell line BRL-3A and rat PBMCs) (Fig. 1a) . After 14 rounds of selection, we sequenced the highly enriched ssDNA pool and chose 20 representative sequences (from 200 clones), on the basis of their predicted secondary structures, for truncation to remove the non-critical bases 17 (Supplementary Table 1 ). Flow cytometry analysis showed that three aptamer candidates (CH2, CH5 and CH6) had good binding ability to osteoblasts (Fig. 1b) with equilibrium dissociation constants (K d ) in the nanomolar-to-picomolar range (Fig. 1c) .
To minimize nuclease degradation, CH2, CH5 and CH6 were modified with 2′-O-methyl-nucleotide substitutions 18, 19 and flow cytometry analysis revealed that they still bound with high affinity to rat osteoblasts but not rat osteoclasts (Fig. 1d) . CH2 and CH6 aptamers also bound to human primary osteoblasts but not human osteoclasts or liver cells (THLE-3) (Supplementary Fig. 1) . We chose the CH6 aptamer because it had satisfactory secondary structure and shorter nucleotide sequences (Fig. 1e) , making it easier to synthesize and conjugate to LNPs-siRNA than CH2.
In vitro analysis of cellular uptake Next, we prepared and characterized CH6 aptamer-functionalized LNPs encapsulating osteogenic Plekho1 siRNA. CH6-LNPs-siRNA had a diameter of 84.0 ± 5.3 nm, encapsulation efficiency above 80%, uniform particle shape, good serum stability, no detectable cytotoxicity and high in vitro osteoblast selectivity (Supplementary Fig. 2 ; Supplementary Table 2) . A random sequence (Rd) served as the negative control aptamer. We labeled Plekho1 siRNA with Cy3 and investigated the effect of the CH6 aptamer versus the Rd aptamer on the cellular uptake of siRNA. The most intense fluorescence signals were detected in osteoblasts incubated with CH6-LNPs-siRNA, and fluorescence signals were rarely observed in osteoblasts treated with no aptamer-conjugated LNPs-siRNA or Rd-LNPs-siRNA (Fig. 2a) . Pretreatment of osteoblasts with free CH6 aptamer resulted in a significantly decreased fluorescence signal of CH6-LNPs-siRNA in osteoblasts (P < 0.05; Fig. 2a) . We also examined the Plekho1 gene knockdown efficiency of different siRNA formulations in osteoblasts. The gene knockdown efficiency for CH6-LNPssiRNA was significantly higher than other siRNA formulations (P < 0.05) (Fig. 2b) .
To investigate the cellular mechanism through which CH6-LNPs-siRNA is taken up by osteoblasts, we labeled Plekho1 siRNA with Cy3 and incubated osteoblasts with different siRNA formulations in the presence of Alexa Fluor 488-labeled endocytic markers 20 . We detected by confocal microscopy numerous instances of co-localization of siRNA with transferrin (a marker for clathrinmediated endocytosis) and dextran (a marker for macropinocytosis), but not with choleratoxin (a marker for caveolae-mediated endocytosis) in osteoblasts incubated with CH6-LNPs-siRNA (Fig. 2c) , indicating that CH6-LNPs-siRNA can be taken up via clathrin-mediated endocytosis as well as by macropinocytosis. In contrast, Rd-LNPs-siRNA (Supplementary Fig. 3a) and LNPs-siRNA (data not shown) were found to enter osteoblasts only via clathrin-mediated endocytosis. Chemical inhibition experiments 21 confirmed these findings from the confocal imaging (Supplementary Fig. 3b,c) . Additionally, confocal images showed that CH6-LNPs-siRNA induced membrane ruffling and lysosome escape of siRNA (attributes of macropinocytosis 22 ) in osteoblasts, but we did not observe this for either LNP-siRNA or Rd-LNP-siRNA ( Supplementary Fig. 3d,e) .
Tissue distribution and cell-specific delivery in vivo We used biophotonic imaging technology to examine the tissue distribution of Cy3-labeled siRNA delivered by different carriers. At each of the time points examined, fluorescence signal intensity of CH6-LNPs-siRNA in bone was significantly higher, whereas the fluorescence signal intensities in liver and kidney were significantly lower when compared to LNPs-siRNA or Rd-LNPs-siRNA, which was consistent with quantitative analysis by a fluorescence microplate reader system (P < 0.05) (Fig. 3a,b; Supplementary Fig. 4a) . Very low fluorescence signals in the heart, spleen and lungs were detected in all administration groups (Fig. 3a,b) .
To investigate whether CH6 could facilitate delivery of siRNA in an osteoblast-selective manner in vivo, we examined the co-localization of Cy3-labeled siRNA and markers of osteoblasts (alkaline phosphatase (Alp) 23 and osteocalcin (OCN) 24 ) and osteoclasts (osteoclast-associated receptor (Oscar) 25, 26 and cathepsin K 27 ) in cryosections from the distal femurs of rats injected with different siRNA formulations. We found numerous instances of co-localization of siRNA with Alp + or OCN + cells in rats when CH6-LNPs-siRNA were administered, whereas there were few instances of such overlapping staining in rats when LNPs-siRNA or Rd-LNPs-siRNA were administered ( Fig. 3c;  Supplementary Fig. 4b) . Furthermore, we found no obvious overlapping staining for siRNA and Oscar + or cathepsin K + cells in rats treated with CH6-LNPs-siRNA. There were, however several instances of overlapping staining for siRNA and Oscar + or cathepsin K + cells in rats treated with LNPs-siRNA or Rd-LNPs-siRNA ( Fig. 3d;  Supplementary Fig. 4c ). We also examined the cellular distribution of siRNA in hepatocytes and the MPS (PBMCs and Kupffer cells); CH6 reduced the uptake of siRNA by hepatocytes, Kupffer cells and PBMCs (Supplementary Fig. 4d,e) . Compared to (AspSerSer) 6 -liposomesiRNA, all LNP-based siRNA delivery systems exhibited weaker fluorescence intensities in the liver (Supplementary Fig. 4d ). Fig. 4a; Supplementary Fig. 5a ). Results from laser-capture microdissection (LCM) in combination with real-time PCR also showed that CH6 could facilitate Plekho1 gene knockdown in OCN + or Alp + cells (Fig. 4b,c; Supplementary Fig. 5b ).
In vivo gene knockdown and dose-response pattern
We also determined the dose-response pattern and persistence of Plekho1 gene silencing in OCN + cells sorted from rats administered with CH6-LNPs-siRNA, LNPs-siRNA, Rd-LNPs-siRNA or (AspSerSer) 6 -liposome-siRNA. The Plekho1 mRNA level decreased in a dose-dependent manner and was lowest (~20% of baseline) in rats administered with CH6-LNPs-siRNA at an siRNA dose of 1.0 mg kg −1 when compared to the other LNPs-based siRNA formulations or (AspSerSer) 6 -liposome-siRNA (Fig. 4d) . After a single injection of siRNA formulations at an siRNA dose of 1.0 mg kg −1 , our results showed that CH6-LNPs-siRNA maintained a low Plekho1 mRNA level (<50% of the Plekho1 mRNA level at baseline) for a longer time (~12 d) when compared to the other LNPs-based siRNA formulations or to (AspSerSer) 6 -liposome-siRNA (~7 d) (Fig. 4e) .
Bone anabolic action
We administered six periodic injections of Plekho1 siRNA (1.0 mg kg −1 ) encapsulated in LNPs-based carriers to ovariectomized (OVX) rats at an interval of once per week and performed in vivo microcomputed tomography (microCT) scanning every 3 weeks during the treatment period (Supplementary Fig. 6a) . A statistical analysis of the in vivo microCT data by repeated-measures ANOVA showed that both the 'time effect' and the 'time by group interaction effect' were substantial for all of the examined variables, indicating both considerable changes in the examined variables over time and remarkably npg different change patterns over time among the examined groups after the administration. After treatment, all the in vivo microCT parameters, including bone mineral density (BMD), relative bone volume (BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), trabecular number (Tb.N) and structural model index (SMI), were obviously improved and were nearly restored to the pre-surgery levels in the OVX + CH6-LNPs-siRNA group when compared to the OVX + Rd-LNPs-siRNA group (P < 0.05) ( Fig. 5a; Supplementary Fig. 6b ).
Better-organized microarchitecture and higher bone mass were consistently found in trabecular bone from the OVX rats treated with CH6-LNPs-siRNA when compared to Rd-LNPs-siRNA (Fig. 5b) . Histomorphometric analysis further demonstrated that the mineral apposition rate (MAR), bone formation rate (BFR/BS), osteoblast surface (Ob.S/BS) and osteoblast number (Ob.N/B.Pm) were significantly increased from baseline and were obviously higher in the OVX + CH6-LNPs-siRNA group when compared to the OVX + Rd-LNPssiRNA group after 6 weeks of siRNA treatment (P < 0.05) ( Fig. 5c;  Supplementary Fig. 6c) . A larger width between the xylenol and the calcein labeling bands was consistently found in the OVX rats treated with CH6-LNPs-siRNA compared to Rd-LNPs-siRNA (Fig. 5d) . No significant difference between Oc.S/BS and Oc.N/B.Pm was found among the siRNA groups (P > 0.05; Supplementary Fig. 6c) . Results from mechanical testing, bone turnover marker assays and microCT examination of cortical bone and fifth vertebrae also evidenced that CH6-LNPs-siRNA achieved a better therapeutic effect when compared to the other siRNA groups (Supplementary Fig. 6d-g ).
We administered six periodic injections of Plekho1 siRNA (1.0 mg kg −1 ) encapsulated in LNPs, Rd-LNPs, CH6-LNPs or (AspSerSer) 6 -liposome to 6-month-old female healthy SpragueDawley rats at an interval of once per week. Results from microCT examination and bone turnover marker assays showed that CH6-LNPs-siRNA significantly improved bone formation and bone mass when compared to other LNPs-based siRNA formulations or (AspSerSer) 6 -liposome-siRNA (P < 0.05) (Supplementary Fig. 7) . No obvious toxicity and immune response were found in rats after either a single dose or multiple doses of CH6-LNPs-siRNA (Supplementary Table 4 ; Supplementary Fig. 8 ).
DISCUSSION
To our knowledge, this is the first report of aptamer-functionalized lipid nanoparticles that can directly target osteoblasts for osteogenic siRNA delivery, and as such these findings may help enable the development of RNAi-based bone anabolic therapies. Relevant to its translational potential, the aptamer CH6 specifically targets both rat and human osteoblasts.
CH6-LNPs-siRNA achieved better gene silencing and bone anabolic action when compared to (AspSerSer) 6 -liposome-siRNA (Supplementary Fig. 7) . This difference could be partly explained by the distinct mechanisms responsible for targeted delivery. The (AspSerSer) 6 moiety was designed to target the physiochemical features of the bone formation surface, and as such it targeted osteoblasts at a tissue level. In contrast, the CH6 aptamer was selected to directly target osteoblasts at cellular level, which is more specific and efficient.
Mechanistically, we found that the CH6 aptamer specifically induced macropinocytosis and facilitated siRNA entry in osteoblasts, which was evidenced by the co-localization of the encapsulated siRNA with a macropinocytosis marker, and by the fact that macropinocytosis inhibitors mediated blockade of siRNA cellular uptake and membrane ruffling appearance. Confocal imaging data suggested that the CH6 aptamer facilitated lysosome escape of siRNA, which reflects another feature of macropinocytosis 22 . Taken together, macropinocytosis induced by the CH6 aptamer can also partially explain the high gene knockdown efficiency and enhanced bone anabolic action of CH6-LNPs-siRNA.
In summary, CH6 aptamer-functionalized LNPs update targeted delivery systems from a tissue level to a cellular level, which facilitates the clinical translation of an RNAi-based bone anabolic strategy.
METHODS
Methods and any associated references are available in the online version of the paper. 
